» Articles » PMID: 18759728

Migraine Prophylaxis

Overview
Journal Med J Aust
Specialty General Medicine
Date 2008 Sep 2
PMID 18759728
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

There is a wide array of options for migraine prophylaxis; many of the available drugs are clearly proven to be effective and yet are underused in Australia. "New" drugs which are gaining favour for migraine prophylaxis include topiramate, candesartan, gabapentin and botulinum toxin. The evidence for efficacy is excellent for topiramate and reasonably good but limited for candesartan and gabapentin. The use of botulinum toxin is controversial and has gained substantial popularity through anecdotal experience rather than convincing published evidence. Transformed or chronic migraine with medication overuse is a particularly difficult problem. New strategies to aid in medication withdrawal are reviewed. The approach to menstrual migraine and migraine with prominent aura may differ from that for typical migraine. Novel approaches are being explored for these problems.

Citing Articles

Inflammo-immune perspective on the association of eight migraine risk factors with migraine: a multi-omics Mendelian randomization study.

Zhao J, Chen R, Luo M, Gong H, Li K, Zhao Q Front Neurol. 2024; 15:1440995.

PMID: 39170074 PMC: 11335614. DOI: 10.3389/fneur.2024.1440995.


Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial.

Shibata M, Nihira A, Tanji Y, Ozeki A, Imagawa H, Komori M Neurol Ther. 2023; 12(6):2007-2019.

PMID: 37698836 PMC: 10630272. DOI: 10.1007/s40120-023-00534-0.


Variation in Endpoints in FDA Medication Approvals: A Review of Acute and Preventive Migraine Medications.

Sharpless L, Kesselheim A, Orr S, Darrow J Neurology. 2023; 101(10):e989-e1000.

PMID: 37438124 PMC: 10491441. DOI: 10.1212/WNL.0000000000207544.


Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine.

Igarashi H, Shibata M, Ozeki A, Day K, Matsumura T J Pain Res. 2021; 14:3555-3564.

PMID: 34815708 PMC: 8605884. DOI: 10.2147/JPR.S326905.


Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial.

Rahimdel A, Mellat A, Zeinali A, Jafari E, Ayatollahi P Iran J Med Sci. 2014; 39(2 Suppl):171-7.

PMID: 24753639 PMC: 3993044.